Core Achievements in 2025 - The company achieved significant milestones in 2025, focusing on R&D innovation, regulatory approvals, and operational excellence to enhance competitiveness in the veterinary vaccine market [4][5] - Four new patents were granted, and ten new patent applications were filed to sustain the innovation pipeline [5] - The company received two National Category I and one National Category III New Veterinary Drug Registration Certificates, enhancing its product portfolio and market position [5] - Seven new product approval licenses were secured, expanding offerings across swine, poultry, cattle, and sheep [5] - The company established the Jilin Province Animal Vaccine Science and Technology Innovation Center with government funding of RMB800,000 [5] - The flagship product "Zhengyuanzhen" was awarded "Excellent Vaccine Product of the Year" at the 2025 China Swine Industry Glory List [6] International Market Expansion - The company submitted registration materials for poultry vaccines in Egypt, Pakistan, and Vietnam, with approvals expected in 2026 [12] - A dedicated swine health business unit was established to enhance customer engagement and support key accounts [12] Production Capabilities and Digital Transformation - The company upgraded its bacterial inactivated vaccine production line to include bacterial culture subunit vaccine capabilities [12] - Key production processes were computerized to improve manufacturing efficiency and product quality consistency [12] Strategic Outlook for 2026 - The company plans to deepen strategic customer engagement and strengthen its product portfolio with solution-based marketing [13][14] - A merger and acquisition strategy will focus on the companion animal sector to broaden the product portfolio and enhance capabilities [17] - The company aims to solidify market leadership of its core product and advance the development of new vaccines [18]